BIOREGULATORY MEDICINE

This documentary has been produced to promote wider knowledge of LDN (Low Dose Naltrexone). Hear from several practioners on how they use LDN with their patients and witness 2 remarkable stories on how LDN has changed the lives of a 8 year old Jacob Valazquez in Miami and Sarah Morton in the UK who was suffering from Fibromyalgia.

LDN is widely used for autoimmune disorders such as multiple sclerosis (MS), Crohn's disease, fibromyalgia, Hashimoto's thyroiditis, and other inflammatory and chronic disorders. View this scientific animation, produced by LDNscience, explaining how it works. LDNscience.org, launched in 2009, is a public information project of the MedInsight® Research Institute. Learn more at ldnscience.org

Interview with Bernard Bihari, MD: Low-dose Naltrexone for Normalizing Immune System Function Bernard Bihari, MD, (1931-2010) was the discoverer of the clinical effects of low-dose naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr Bihari discovered the significant effectiveness of low-dose naltrexone (LDN) in protecting the battered immune systems of those who were infected. With that knowledge, he entered private practice in an attempt to counter the then untreatable disease. As Dr Bihari explains below, the immune-system normalizing effect of the drug application he discovered applies to a wide range of autoimmune disorders. This interview was provided by Dr Bihari’s widow, from a videotape discovered after his death. The interview was transcribed and curated by Julia Schopick, author of Honest Medicine (www.honestmedicine.com) and champion of effective, cost-efficient treatments that are neglected by current practice. Content Courtesy of Alternative Therapies, Vol. 19, No 2 Since this interview, TNI BioTech has obtained the rights to the clinical data and the transfer of the Investigational New Drug (IND) and orphan drug designation for LDN from the US Food and Drug Administration for pancreatic cancer and Crohn’s disease. For more go to tnibiotech.com Bernard Bihari, MD, (1931-2010) was the discoverer of the clinical effects of low-dose naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr Bihari discovered the significant effectiveness of low-dose naltrexone in protecting the battered immune systems of those who were infected. With that knowledge, he entered private practice in an attempt to counter the then untreatable disease. As Dr Bihari explains below, the immune system normalizing effect of the drug application he discovered applies to a wide range of autoimmune disorders. This interview was provided by Dr Bihari’s widow, from a videotape discovered after his death. The interview was transcribed and curated by Julia Schopick, author of Honest Medicine (http://www.honestmedicine.com) and champion of effective, cost-efficient treatments that are neglected by current practice. (Altern Ther Health Med. 2013;19(2):56-65.) Since this interview, TNI BioTech has obtained the rights to the clinical data and the transfer of the Investigational New Drug (IND) and orphan drug designation for LDN from the US Food and Drug Administration for pancreatic cancer and Crohn’s disease. For more go to tnibiotech.com Since Dr. Bihari’s passing in 2010, a LDN Research Trust was set up by a group of multiple sclerosis patients to initiate clinical trials of LDN. The organization has assisted more than 14,000 patients to obtain LDN from a general practitioner or neurologist through the National Health Service in the UK or by prescription in other countries including the United States, Canada, Australia, New Zealand and the West Indies. The organization says they have helped patients with MS, Crohn’s, IBS. ME, some cancers and other immune-related diseases. For more go to ldnresearchtrust.org and YouTube.com/LDNScience.